Science Pool

Evotec partner Kazia Therapeutics announces full regulatory approval for Phase I study of EVT801

Evotec partner Kazia Therapeutics Limited today announced that the planned phase I study for EVT801 has received full approval from L’Agence Nationale de Sécurité du Médicament et des Produits de Santé (“ANSM”), the French regulatory agency. The study is expected to open to recruitment by the end of CY2021.
Read More

Generated by Feedzy